Hepatology

The US is close to eliminating hepatitis B in children, but chronic adult infection and a shifting vaccine policy threaten that progress.

Naim Alkhouri, MD, discusses real-world resmetirom data in MASH, GLP-1 combinations, and using ANTICIPATE-NASH in practice.

Resmetirom boosts MASH cardiovascular protection, lowering LDL cholesterol and Lp(a) even on statins, and pushes routine Lp(a) testing.

New data showed durable hepatitis D virus RNA suppression through 96 weeks with tobevibart plus elebsiran, while higher BMI appeared to affect ALT normalization.

Two posters presented at EASL 2026 clarify where peginterferon alfa-2b fits in therapy for patients with chronic hepatitis B.

Heiner Wedemeyer, MD, offered an unflinching assessment of viral hepatitis medicine, celebrating landmark breakthroughs while issuing a clear warning that the field is failing the populations it set out to protect.

New data highlight pevifoscorvir’s potent antiviral activity and sustained hepatitis B antigen suppression lasting up to 96 weeks after treatment.

Meena Bansal, MD, discusses the evolving MASH pipeline and why precision phenotyping, biomarkers, and cardiovascular outcomes data remain critical gaps.

Phase 2 data for DD01 and pemvidutide show liver-directed MASH benefits beyond weight loss, with strong tolerability heading into phase 3.

Full results from the pivotal B-Well 1 and B-Well 2 phase 3 trials confirm that bepirovirsen delivers statistically significant functional cure rates in chronic hepatitis B.

Evidence suggests new therapies like GLP-1 receptor agonists, initially approved to treat obesity and diabetes, can also benefit patients with liver disease.

The LPI/GPR55 axis is a key driver of MAFLD/MASH progression by promoting liver fat accumulation, inflammation, and fibrosis.

In a cohort of veterans with steatotic liver disease, patients with metabolic- and alcohol-associated liver disease had the lowest incidence of cirrhosis.

New research highlights the effectiveness of targeted therapies for metabolic dysfunction–associated steatohepatitis (MASH), guiding treatment decisions and trial designs.

New research reveals gut microbiome changes in children with obesity signal liver disease progression, offering insights for early detection and intervention.

Researchers unveil a spatial multi-omics atlas revealing immune cell interactions and lipid metabolism's role in metabolic liver diseases, offering new therapeutic insights.

FDA granted breakthrough therapy designation to pemvidutide based on its potential in treating metabolic dysfunction–associated steatohepatitis (MASH).

A new analysis reveals effective therapies for reducing liver fat in metabolic dysfunction-associated steatohepatitis and highlights MRI-PDFF as a key measurement tool.

These patients had a higher spleen-to-liver stiffness ratio than those with alcohol-related liver disease, warranting a closer look at testing.

By 2040, advanced metabolic dysfunction–associated steatohepatitis (MASH) is projected to rise by at least 20% in the 9 countries assessed.

The treatment also showed signs of metabolic gains, with more benefit seen with the 50-mg dose than the 28-mg.

The global incidence, deaths, and disability-adjusted life years tied to metabolic dysfunction–associated steatohepatitis (MASH)-related liver cancer have more than doubled in older adults since 1990, with a heavy impact on low- and middle-income countries.

Approval was based on part 1 of the ESSENCE trial, with part 2 results expected in 2029.

The risk of fatty liver disease is especially high in patients with multiple cardiometabolic risk factors who undergo gallbladder removal, according to research from South Korea.

TACE combined with SBRT enhanced survival rates in patients with large hepatocellular carcinoma tumors, offering promising treatment insights.